DEF: Xeris Biopharma Holdings 2026 Annual Meeting Notice

Xeris Biopharma Holdings announces its 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026, with key proposals including director elections and auditor ratification.

Summary

• Xeris Biopharma Holdings, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 4, 2026, at 8:00 a.m. Central Time.
• The meeting will cover the election of two Class II directors, ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
• Stockholders of record as of April 14, 2026, are eligible to vote.
• Registration for the virtual meeting is required by June 3, 2026, 5:00 p.m. Eastern Time.
• Proxy materials are being furnished over the internet, with a Notice of Internet Availability of Proxy Materials being mailed around April 23, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong performance metrics in 2025, exceeding revenue targets, achieving adjusted EBITDA positivity, and significant TSR outperformance, alongside positive pipeline developments.

Positives

• The virtual meeting format is intended to increase accessibility and encourage participation from stockholders.
• The company is leveraging SEC rules to provide proxy materials over the internet, reducing costs and environmental impact.
• The board of directors has determined that all directors, except the CEO, are independent.
• The Audit Committee has a designated financial expert.
• The Compensation Committee has engaged an independent compensation consultant (Aon) and reviewed their work for conflicts of interest.
• The company has adopted a clawback policy for incentive compensation.
• The company has anti-hedging and anti-pledging policies for its securities.
• The company's pay-for-performance philosophy is supported by a significant portion of executive pay being variable and at-risk.
• The company's 2025 corporate objectives were achieved or exceeded, with a 120% corporate performance achievement level for NEOs.
• Total revenue in 2025 was $291.8 million, exceeding guidance.
• Total product revenue grew by approximately 43.9% in 2025.
• Recorlev net revenue increased by approximately 117% in 2025.
• Gvoke net revenue increased by approximately 14% in 2025.
• XP-8121 pipeline development advanced with an expedited approval of its first Orange Book patent and positive FDA interactions.
• The CEO pay ratio is 21.73:1, indicating a relatively contained gap between CEO and median employee compensation.

Negatives

• Dr. Jeffrey Sherman, a Class II director, will not stand for re-election, and the board size will be reduced to seven members.
• Keveyis net revenue decreased by approximately 4% in 2025 due to unfavorable net pricing.
• The company has no formal policy regarding board diversity.
• The company's 2025 peer group analysis for compensation was based on companies with market capitalizations up to $1.5 billion, revenue between $100.0 and $600.0 million, and up to 1,000 employees, which may not fully capture the competitive landscape for all roles.
• The company's 2025 Pay Versus Performance table shows a significant divergence between compensation actually paid to the PEO and the Summary Compensation Table total, and also between compensation actually paid to non-PEO NEOs and their Summary Compensation Table total, particularly in 2025.

Risks

• Actual results could differ materially from forward-looking statements due to various risks and uncertainties, as described in the 2025 Annual Report on Form 10-K.
• The company faces risk exposures including financial, accounting, product development and commercialization, privacy, security, cybersecurity, competition, legal, compliance, intellectual property, and regulatory risks.
• The company's bylaws allow for removal of directors only for cause by a two-thirds vote of outstanding shares, which could be a high threshold.
• The company's stock ownership guidelines require non-employee directors to hold shares equivalent to three times their annual cash retainer by the fifth anniversary of the guidelines' effective date or their appointment, with specific rules on what counts towards this requirement.
• The company's insider trading policy prohibits hedging and pledging of its stock, which could limit some investors' strategies.
• The company's employment agreements include provisions for severance payments and accelerated vesting of equity upon termination without cause or resignation for good reason, especially in connection with a change in control, which could represent a significant financial obligation.

Future Outlook

The filing does not contain specific forward-looking financial guidance but discusses advancements in pipeline development, such as XP-8121, with projected peak sales between $1.0 billion and $3.0 billion, and a plan to fund it through commercialization. The company also anticipates initiating a first patient dose in Phase 3 for XP-8121 in the second half of 2026.

Management Comments

• "2025 was a transformational year for Xeris. Across the organization, we executed with discipline and focus, advancing our strategic priorities and driving measurable progress throughout the business."
• "Most importantly, we have reached a defining milestone, financial sustainability introducing EBITDA as a new key measure of the companys financial performance."
• "The Company outperformed its key financial targets, with both total product revenue and total revenue increasing by approximately 44%, and we remained adjusted EBITDA positive in every quarter of 2025."
• "In addition, with a focus on our pipeline, development and readiness of XP-8121 advanced tremendously with expedited approval of our first Orange Book patent, significant and positive alignment with the U.S. Food and Drug Administration, or the FDA, and a strategic plan prepared to fully fund XP-8121 to and through commercialization."

Industry Context

StockSavvy.ai notes that Xeris Biopharma Holdings is operating in the competitive biopharmaceutical sector, where pipeline development, regulatory approvals, and financial sustainability are critical. The company's focus on advancing XP-8121 and achieving financial sustainability through positive adjusted EBITDA aligns with industry trends of seeking to de-risk development and commercialization pathways.

Comparison to Industry Standards

• The 2025 peer group for executive compensation analysis included 16 companies: ADMA Biologics, ANI Pharmaceuticals, Aquestive Therapeutics, Assertio, Coherus BioSciences, Collegium Pharmaceuticals, Deciphera Pharmaceuticals (acquired), Harrow, Inc., Ironwood Pharmaceuticals, Karyopharm Therapeutics, MacroGenics, Mirum Pharmaceuticals, Ocular Pharmaceuticals, Rhythm Pharmaceuticals, Travere Therapeutics, UroGen Pharma, and Y-mAbs Therapeutics.
• The peer group was selected based on market capitalization (up to $1.5 billion), revenue ($100.0 - $600.0 million), and employee headcount (up to 1,000).
• The company's Total Shareholder Return (TSR) for 2025 was 159.55%, significantly outperforming the Nasdaq Biotechnology Index (Peer Group TSR) of 124.75%.
• The company's 2025 revenue of $291.8 million exceeded its guidance of $255.0 to $275.0 million.
• The company's adjusted EBITDA of $59.4 million for 2025 demonstrates a move towards profitability, a key metric in the biopharma industry.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a Related Person Transaction Policy reviewed by the Audit Committee. Transactions are approved if on terms no less favorable than with unaffiliated third parties.
• Certain transactions with companies where a related person is a non-executive employee, director, or <10% owner are pre-approved if aggregate amount is within specified limits and terms are favorable.

Stakeholder Impact

• Shareholders: The election of directors, ratification of auditors, and advisory vote on executive compensation directly impact shareholder governance and oversight. Strong financial performance and pipeline advancements are intended to drive shareholder value.
• Employees: The compensation discussion highlights a focus on attracting and retaining talent, with broad-based benefits and equity awards. Performance-based bonuses and equity grants are tied to corporate and individual achievements.
• Management: Executive compensation is structured to align with strategic objectives and stockholder interests, with a significant portion being performance-based and at-risk.

Next Steps

• Stockholders to vote on the election of two Class II directors at the Annual Meeting.
• Stockholders to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• Stockholders to approve, on a non-binding advisory basis, the compensation of named executive officers.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Form 8-K within four business days following the meeting.
• Stockholders may submit proposals for the 2027 annual meeting by December 24, 2026.

Key Dates

Recommendation

The filing indicates strong operational and financial performance in 2025, with significant TSR outperformance and positive pipeline developments. However, the proxy statement primarily concerns governance matters and executive compensation, rather than new strategic initiatives or financial results that would warrant a strong buy/sell recommendation. The company is moving towards financial sustainability, but further execution on pipeline and commercialization is key. A 'hold' recommendation reflects the positive trajectory while acknowledging the need for continued execution and monitoring of future results.

Keywords

Xeris Biopharma Holdings, Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, Executive Compensation, Stockholder Meeting, Virtual Meeting, SEC Filing, Schedule 14A